Table 3 Radiobiological modeling results for tumor control probability and normal tissue complication probability across competing dose-fractionation regimens
Outcome | PTV coverage prioritized | OAR constraints prioritized | ||||
|---|---|---|---|---|---|---|
50 Gy in 5 | 60 Gy in 8 | 60 Gy in 15 | 50 Gy in 5 | 60 Gy in 8 | 60 Gy in 15 | |
tumor control | 92.9 (89.7–99.1) | 92.4 (84.7–95.3) | 52.0 (48.3–55.7) | 60.3 (31.5–80.1) | 65.7 (39.2–81.4) | 47.8 (41.0–53.3) |
acute esophagitis ≥ grade 2 | 1.18 (0.45–3.98) | 1.05 (0.44–2.44) | 0.86 (0.42–1.85) | 0.72 (0.34–1.35) | 0.77 (0.39–1.40) | 0.72 (0.42–1.49) |
symptomatic pneumonitis (all grades) | 4.30 (1.79–11.6) | 4.09 (1.90–11.1) | 3.68 (1.53–13.8) | 3.44 (2.24–8.03) | 3.45 (1.75–8.08) | 2.97 (1.54–6.84) |
pericarditis or pericardial effusion | 0.01 (0.00–0.08) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) |
proximal bronchial tree toxicity (grade 4 or 5) | 49.7 (15.0–70.0a) | 42.7 (5.0–70.0a) | 4.0 (0.0–10.0) | 0.0 (0.0–0.0) | 0.0 (0.00–0.0) | 1.3 (0.0–5.0) |
uncomplicated tumor control | 46.7 (27.6–77.6) | 53.5 (25.4–90.4) | 49.9 (44.6–54.0) | 60.3 (31.5–80.1) | 65.7 (39.2–81.4) | 47.2 (41.0–52.8) |